A carregar...
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial [Image: see text] [Image: see text]
OBJECTIVE: B cells and the humoral immune system have been implicated in the pathogenesis of multiple sclerosis (MS). This study sought to evaluate the efficacy, safety, and tolerability of add-on therapy with rituximab, a monoclonal antibody that depletes circulating B cells, in subjects with relap...
Na minha lista:
| Main Authors: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Academy of Neurology
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2882224/ https://ncbi.nlm.nih.gov/pubmed/20530322 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e3181e24373 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|